Breast Cancer Recurrence Risk Assessment
Transcriptome Gene Expression Testing for Breast Cancer
Background
U.S. Success Story
In 2005, Gene Health introduced the Breast Cancer 21-Gene Test Recurrence Score Test
- Serving 2 million early breast cancer patients with HR+, HER2-, and N0 in the United States;
- Approximately 600,000 (30%) low-risk patients were screened to avoid ineffective chemotherapy;
- Save 300 billion RMB for ineffective chemotherapy drugs for the medical system.
Recommended by Guidelines
- 21-Gene Test Listed as Recommended Molecular Test in NCCN Breast Cancer Treatment Guidelines;
- Ten-year follow-up data show that the recurrence score of 21-gene testing has been extremely successful.
Rapid Growth
Other similar products such as 70-gene, 50-gene and 12-gene have been clinically applied in western developed countries, and some of them have been introduced to China through agents.
The market urgently needs
At present, there is a lack of products for Asian populations, and Luwei will fill this gap in this field by conducting clinical validation and promotion for Asian populations.
Product Line
1. RNA expression detection in hormone receptor-positive early-stage breast cancer patients
Help HR+, HER2-, N0 early breast cancer patients determine whether chemotherapy is needed; Determine whether chemotherapy and endocrine therapy respond.
a. Recurrence score (21 genes)
b. Chemotherapy response score (20 genes)
c. Endocrine therapy response score (23 genes)
2. RNA expression detection in patients with triple negative breast cancer (TNBC)
Help patients with triple-negative breast cancer to determine if chemotherapy is needed and whether chemotherapy responds.
a. Recurrence score (16 genes)
b. Chemotherapy response score (19 genes)
Technical advantages
- The technology leader is the core member of the "breast cancer 21-gene recurrence score" of American gene health, which took more than 4 years to complete independent research and development and a number of invention patents.
- The original model based on the re-optimization of the Asian population applies the latest scientific research results in the field of breast cancer molecules.
- Based on NGS sequencing, the number of modeling samples is larger, and the gene screening and modeling algorithm of independent patent is used.
Detect items
| Cancer type | Prognosis | Specificity | Sensitivity | AUC | 5-year survival rate | Use |
|---|---|---|---|---|---|---|
| Low risk | ||||||
| HR+, HER2-, N0 | Relapse score (RS) | 79% | 78% | 0.85 | 97% | Low-risk patients avoid chemotherapy. |
| Response to chemotherapy | 89% | 88% | 0.94 | 90% | Chemotherapy for patients with high response scores. | |
| Response to endocrine therapy | 89% | 85% | 0.93 | 85% | Endocrine therapy for patients with high response scores. | |
| Triple-negative breast cancer (TNBC) | Relapse score (RS) | 91% | 95% | 0.96 | 90% | Aggressive treatment for high-risk patients, such as high-dose chemotherapy; Low-risk patients are treated conservatively. |
| Response to chemotherapy | 94% | 95% | 0.98 | 88% | Chemotherapy or high-dose chemotherapy for patients with high response scores; For patients with low response scores other treatment options, chemotherapy regimens should be used with caution. | |
| Single gene or combination gene expression | PARP1, ATR, ATM, ER, PGR, HER2, MKI67, BRCA; PI3K, AKT, mTOR, PI3KCA; CDK4, CDK6; VEGF, TACSTD2, PD-1, PD-L1 etc. | Medication guidance | ||||